Why Nordicus Partners Corporation’s (NORD) Stock Is Down 15.70%
As of Thursday, November 05, Nordicus Partners Corporation’s NORD share price has dipped by 15.70%, which has investors questioning if this is right time to buy.Tudor Pop
Stock Evaluator: Nordicus Partners Corporation (NORD)
Nordicus Partners Corporation NORD
$3.25
-0.48
-12.75%
November 5, 2026 3:55:53 PM
EST
Volume: 19,628
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
NASD | DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Biotechnology |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Nordicus Partners Corporation, a biotech company specializing in developing breakthrough therapeutics for diseases with unmet medical needs in the United States. It develops medicines supporting oral health. The company was formerly known as EKIMAS Corporation and changed its name to Nordicus Partners Corporation in May 2023. Nordicus Partners Corporation was founded in 1993 and is based in Beverly Hills, California.
Commentary & Analysis
Why Nordicus Partners Corporation’s (NORD) Stock Is Down 14.15%
As of Wednesday, November 04, Nordicus Partners Corporation’s NORD share price has dipped by 14.15%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Nordicus Partners Corporation’s (NORD) Stock Is Up 6.25%
As of Tuesday, November 03, Nordicus Partners Corporation’s NORD share price has surged by 6.25%, which has investors questioning if this is right time to sell.Michael Rose
Is Ekimas Corp (NORD) Stock a Good Investment?
Learn more about Ekimas Corp's (NORD) stock grades for Growth and determine whether this Investment Holding Companies stock meets your investment needs.Jenna Brashear
Financial Summary
| Share Statistics | NORD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $63.2 | $214.3 | 19% |
|
| Shares Out (Mil) | 19.2 | 53.9 | 30% |
|
| Institutional Ownership | na | 92.9% | na |
|
| Float (Mil) | na | 41.4 | na |
|
| Beta | -0.48 | 0.96 | 2% |
|
| Avg Daily Volume (000s) | 26 | 506 | 24% |
|
| Price Change (52-week) |
(63.5%) | 43.9% | 14% |
|
| Growth | NORD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (109.1%) | (10.1%) | 2% |
|
| EPS (5yr) | na | 15.8% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.7%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | NORD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($5) | ($44) | 33% |
|
| EPS (TTM) | ($0.273) | ($1.500) | 31% |
|
| Operating Cash Flow (TTM) (Mil) | ($4) | ($34) | 26% |
|
| Net Cash Flow (TTM) (Mil) | $0 | $1 | 43% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $78 | $172 | 19% |
|
| Valuation | NORD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.01 | 2.00 | 27% |
|
| P/E | na | 18.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | NORD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.3% | na |
|
| Net Margin | na | (63.5%) | na |
|
| ROA | (6.8%) | (47.5%) | 28% |
|
| ROE | (8.1%) | (53.3%) | 28% |
|
| Liabilities to Assets | 15.9% | 29.6% | 10% |
|
| F-Score | 3 | 2 | 18% |
|
Nordicus Partners Corporation did not pass any screens on 11/5/2026.
